Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort

ObjectiveTo compare the real-world clinical efficacy and safety of interleukin (IL)-17A inhibitors (secukinumab [SEC] and ixekizumab [IXE]) versus the IL-23 inhibitor guselkumab (GUS) in patients with nail psoriasis, with a focus on site-specific biologic therapeutic responses (nail matrix vs. nail...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Xiamei Yan, Minglan Shi, Bin Wang, Lihua Zeng, Huiwei Wang, Jialiang Shi, Yaqian Cui, Suchun Hou
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	Frontiers Media S.A. 2025-04-01
Ráidu:	Frontiers in Immunology
Fáttát:	nail psoriasis dermoscopy IL-17A inhibitors IL-23 inhibitor real-world cohort NAPSI
Liŋkkat:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573715/full
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!